ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor
September 29, 2019
AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--Sep 28, 2019--
Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, today reported results from its non-clinical GLP toxicology program with first-in-class selective TGF-beta inhibitor AVID200 and evidence of TGF-beta target engagement in patients treated with this novel immuno-oncology agent at the European Society of Medical Oncology (ESMO) 2019 Annual Congress in Barcelona.
The presentation detailed for the first time that AVID200 administered at doses of ≥1 mg/kg sequestered its tar...
For access to this article please
sign in or
subscribe.
Reader Comments(0)